The Phase II, US multi-center randomized, double-blind, placebo-controlled study, Mpex 302 is expected to enroll approximately 300 chronic obstructive pulmonary disease (COPD) patients to evaluate the safety, tolerability
This study is designed to compare glycemic control of a standardized liquid meal challenge and insulin pharmacokinetics (PK) after administration of each of four study drugs: Humulin R
The Phase II trial, called Explore Xa, is a multi-national, double-blind, dose-finding study that will enroll approximately 500 patients and assess three once-daily doses of betrixaban (40mg, 60mg,
The top-line results from the recently completed multi-center, randomized, double-blind, placebo-controlled Phase II trial indicated a statistically significant reduction in recurrences of C difficile associated diarrhea (CDAD) when
According to the company, the availability of AuroraSpectroscopy will provide Aurora breast magnetic resonance imaging (MRI) the capability to perform in vivo breast MR spectroscopy (MRS) and MR
The purpose of the trial is to evaluate whether ATI-5923 is superior to warfarin in its ability to maintain patients within a target therapeutic range of the level
The new medical center will be situated at Sonapur, in Al Ghusais. The Department of Health and Medical Services (DOHMS) expects the center to process 5,000 applications daily.
Approximately 36 patients were enrolled into this Phase II open-label, multi-center trial that is evaluating the efficacy and safety of CR011-vcMMAE 1.88mg/kg administered intravenously once every three weeks.
The Phase Ib clinical trial was conducted to identify the maximum tolerated dose of BZL101 and to determine the safety and feasibility of the company’s novel, oral, anticancer
Shandong New Medicine Research Institute currently administers a multitude of treatments and is a provider of regenerative medical therapies in China which strategically fits into both NeoStem’s existing
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.